Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin–clavulanate in the treatment of acute bacterial sinusitis

References

• Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis 1996;23: 1209–25
   PubMed Web of Science ®Google Scholar
• Desrosiers M, Klossek JM, Benninger M. Management of acute bacterial rhinosinusitis: current issues and future perspectives. Int J Clin Pract 2006;60: 190–200
   PubMed Web of Science ®Google Scholar
• Leggett JE. Acute sinusitis. When – and when not – to prescribe antibiotics. Postgrad Med J 2004;115: 13–19
   Google Scholar
• Winstead W. Rhinosinusitis. Prim Care 2003;30: 137–54
   PubMed Web of Science ®Google Scholar
• Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005;59: 230–8
   PubMed Web of Science ®Google Scholar
• Anon JB, Jacobs MR, Poole MD, . Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130(1 Suppl):1–45Erratum in: Otolaryngol Head Neck Surg 2004;130:794–6
   PubMed Web of Science ®Google Scholar
• Low DE, Desrosiers M, McSherry J, . A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ 1997;156(Suppl 6):S1–14
   PubMed Web of Science ®Google Scholar
• Rosenfeld RM, Andes D, Bhattacharyya N, . Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007;137(3 Suppl):S1–31
   PubMed Web of Science ®Google Scholar
• Riffer E, Spiller J, Palmer R, . Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin 2005;21: 61–70
   PubMed Web of Science ®Google Scholar
• Siegert R, Gehanno P, Nikolaidis P, . A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94: 337–44
   PubMed Web of Science ®Google Scholar
• Henry DC, Sydnor A, Settipane GA, . Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitis. Clin Ther 1999;21: 1158–70
   PubMed Web of Science ®Google Scholar
• Lasko B, Lau CY, Saint-Pierre C, . Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized trial. J Int Med Res 1998;26: 281–91
   PubMed Web of Science ®Google Scholar
• Clifford K, Huck W, Shan M, . Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Ann Otol Rhinol Laryngol 1999;108: 360–7
   PubMed Web of Science ®Google Scholar
• Adelglass J, deAbate CA, McElvaine P, . Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999;120: 320–7
   PubMed Web of Science ®Google Scholar
• Stefansson P, Jacovides A, Jablonicky P, . Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998;36: 173–8
   PubMedGoogle Scholar
• Camacho AE, Cobo R, Otte J, . Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992;93: 271–6
   PubMed Web of Science ®Google Scholar
• Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993;72: 804–10
   PubMedGoogle Scholar
• Haye R, Lingaas E, Hoivik HO, Odegard T. Azithromycin versus placebo in acute infectious rhinitis with clinical symptoms but without radiological signs of maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1998;17: 309–12
   PubMed Web of Science ®Google Scholar
• Karma P, Pukander J, Penttilä M, . The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1991;27(Suppl A):83–90
   PubMed Web of Science ®Google Scholar
• Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ 1996;313: 325–9
   PubMed Web of Science ®Google Scholar
• Matthews BL, Kohut RI, Edelstein DR, . Evaluation of cefixime in the treatment of bacterial maxillary sinusitis. South Med J 1993;86: 329–33
   PubMed Web of Science ®Google Scholar
• von Sydow C, Savolainen S, Soderqvist A. Treatment of acute maxillary sinusitis – comparing cefpodoxime proxetil with amoxicillin. Scand J Infect Dis 1995;27: 229–34
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther 2006;4: 973–80
   PubMedGoogle Scholar
• Doern GV. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance. Expert Rev Anti Infect Ther 2006;4: 821–35
   PubMedGoogle Scholar
• Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). Diagn Microbiol Infect Dis 2006;56: 69–74
   PubMed Web of Science ®Google Scholar
• Felmingham D, White AR, Jacobs MR, . The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005;56(Suppl 2):ii3–21
   PubMedGoogle Scholar
• Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3. J Infect 2005;51: 355–63
   PubMed Web of Science ®Google Scholar
• Poole MD. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility. Am J Med 2004;117(Suppl 3A):29–38S
   Google Scholar
• White AR, Kaye C, Poupard J, . Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53(Suppl 1):i3–20
   PubMed Web of Science ®Google Scholar
• Poole MD, Portugal LG. Treatment of rhinosinusitis in the outpatient setting. Am J Med 2005;118(Suppl 7A):45–50S
   PubMedGoogle Scholar
• Pichichero ME. Short courses of antibiotic in acute otitis media and sinusitis infections. J Int Med Res 2000;28(Suppl 1):25–36A
   Google Scholar
• Kasbekar N, Acharya PS. Telithromycin: the first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 2005;62: 905–16
   PubMed Web of Science ®Google Scholar
• Buchanan P, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003;17: 369–77
   PubMedGoogle Scholar
• Ferguson BJ, Guzzetta RV, Spector SL, Hadley JA. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;131: 207–14
   PubMed Web of Science ®Google Scholar
• Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003;82: 576–90
   PubMedGoogle Scholar
• Roos K, Brunswig-Pitschner C, Kostrica R, . Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002;48: 100–8
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Hamilos DL, Hadley JA, . Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006;118(Suppl 5):S17–61
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for industry. Sinusitis: designing clinical development programs of nonantimicrobial drugs for treatment. 2006. http://www.fda.gov/cder/guidance/7316dft.pdf (accessed 1 February 2008)
   Google Scholar
• International Conference on Harmonisation (ICH). Harmonised Tripartite Guideline. Guideline for good clinical practice10 June1996;E6(R1), http://www.ich.org/LOB/media/MEDIA482.pdf (accessed 31 January 2008)
   Google Scholar
• Taylor DC, Norman GR, Torrance G, . Validation of 5-item instrument for assessing symptom severity in patients with acute bacterial sinusitis. Value Health 2004;7: 766
   Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Center, The Health Institute: 1993
   Google Scholar
• Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Component Summary Measures: A User's Manual. Boston: New England Medical Center, The Health Institute: 1994
   Google Scholar
• US FDA. Telithromycin (marketed as Ketek) Information. Updated February 12, 2007. http://www.fda.gov/CDER/Drug/infopage/telithromycin/default.htm (accessed 31 January 2008)
   Google Scholar
• Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53: 149–57
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 2004;48: 1882–4
   PubMed Web of Science ®Google Scholar
• Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005;18: 125–31
   PubMed Web of Science ®Google Scholar
• Araujo FG, Slifer TL, Remington JS. Inhibition of secretion of interleukin-1α and tumor necrosis factor alpha by the ketolide antibiotic telithromycin. Antimicrob Agents Chemother 2002;46: 3327–30
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Tessier PR, Rubinstein I, Nightingale CH. In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model. Pharmazie 2006;61: 343–7
   PubMed Web of Science ®Google Scholar